|
Glioblastoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
IDH1 mutations are closely related to the development and progression of various human cancers, such as glioblastoma, sarcoma, and acute myeloid leukemia.
|
31836442 |
2020 |
|
Glioblastoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
67 patients aged 70 years or younger, operated between January 2013 and December 2015, with newly diagnosed IDH wild-type GBM and clinical follow-up were retrospectively investigated in this study.
|
31422371 |
2020 |
|
Glioblastoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
IDH-wild-type glioblastoma (GBM) is a disease with devastating prognosis.
|
31736002 |
2020 |
|
Glioblastoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Continuous administration of DS-1001b impaired tumor growth and decreased 2-HG levels in subcutaneous and intracranial xenograft models derived from a glioblastoma patient with IDH1 mutation.
|
31727689 |
2020 |
|
Glioblastoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Predicting TERT promoter mutation using MR images in patients with wild-type IDH1 glioblastoma.
|
30948344 |
2020 |
|
Glioblastoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Anaplastic astrocytoma, IDH-wildtype (AA-IDHwt) was the common molecular subgroup (52.8%), followed by diffuse astrocytoma, IDH-wildtype (DA-IDHwt) and AA, IDH-mutant (AA-IDHmt) (each 16.9%), DA-IDHmt (7.9%), glioblastoma (GBM)-IDHwt (3.3%) and GBM-IDHmt (2.2%).
|
31435963 |
2020 |
|
Glioblastoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
For this reason, it was suggested that immunohistochemistry against IDH1 R132H is sufficient to classify GBM as IDH wild-type in this age group.
|
31758617 |
2020 |
|
Glioblastoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Increased RLIP76 expression in IDH1 wild‑type glioblastoma multiforme is associated with worse prognosis.
|
31746408 |
2020 |
|
Glioblastoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
In application to the glioblastoma dataset from The Cancer Genome Atlas, MHN proposed a novel interaction in line with consecutive biopsies: IDH1 mutations are early events that promote subsequent fixation of TP53 mutations.
|
31250881 |
2020 |
|
Glioblastoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Long noncoding RNA MALAT1 may be a prognostic biomarker in IDH1/2 wild-type primary glioblastomas.
|
31479414 |
2020 |
|
Glioblastoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
U87 human GBM cells were treated with the IC50 concentration of various agents used in the treatment of GBM, including alkylating agents (temozolomide, carmustine, lomustine, procarbazine), inhibitor of topoisomerase I (irinotecan), vascular endothelial and epidermal growth factor receptor inhibitors (cediranib and erlotinib, respectively) anti-metabolite (5-fluorouracil), microtubule inhibitor (vincristine), and metabolic agents (dichloroacetate and IDH1 inhibitor ivosidenib).
|
30989436 |
2020 |
|
Glioblastoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
(3) Results: 21 patients mainly with IDH-wildtype glioblastomas who had been treated with REG were retrospectively identified.
|
31766326 |
2019 |
|
Glioblastoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Consequently, we present a curated panel of 12 readily-usable, genetically-diverse, tumourigenic, patient-derived, low-passage, serum-free cell lines representing the spectrum of molecular subtypes of IDH-wildtype GBM along with their detailed phenotypic characterisation plus a bespoke set of lentiviral plasmids for bioluminescent/fluorescent labelling, gene expression and CRISPR/Cas9-mediated gene inactivation.
|
30894629 |
2019 |
|
Glioblastoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
We therefore examined location-dependent prognostic factors, growth, and recurrence patterns in a consecutive cohort of 285 IDH1-wildtype GBMs.
|
30669568 |
2019 |
|
Glioblastoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
<i>IDH1/2</i> is mutated in ~70⁻80% of lower-grade gliomas and the majority of secondary glioblastomas.
|
30857299 |
2019 |
|
Glioblastoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Widely metastatic IDH1-mutant glioblastoma with oligodendroglial features and atypical molecular findings: a case report and review of current challenges in molecular diagnostics.
|
30738431 |
2019 |
|
Glioblastoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
We studied the association of immunohistochemical expression of hypoxia inducible factor-1 alpha (HIF-1α), telomerase reverse transcriptase (TERT), isocitrate dehydrogenase 1 (IDH1) and tumor protein p53 with overall survival (OS) in glioblastoma patients uniformly treated by standard of care, with adequate follow-up.
|
31258744 |
2019 |
|
Glioblastoma
|
0.200 |
PosttranslationalModification
|
disease |
BEFREE |
TMZ-naïve hypermutated tumors were marked by absence of IDH1 somatic mutation and MGMT promoter (pMGMT) methylation, two genomic traits that were significantly associated with the TMZ-induced hypermutagenic event in glioblastoma, and harbored inherited alterations in the mismatch repair (MMR) machinery.
|
30536544 |
2019 |
|
Glioblastoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Recent DNA methylation analyses revealed a small group of IDH mutant diffuse gliomas exhibiting decreased DNA hypermethylation resulting in substantial unfavorable prognosis comparable to glioblastoma.
|
30937703 |
2019 |
|
Glioblastoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
c-Met Expression Is a Useful Marker for Prognosis Prediction in IDH-Mutant Lower-Grade Gliomas and IDH-Wildtype Glioblastomas.
|
30878754 |
2019 |
|
Glioblastoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
While IDH1/2 mutations and G-CIMP are commonly retained during tumor recurrence, recent work has uncovered losses of the IDH1 mutation in a subset of secondary glioblastomas.
|
31292202 |
2019 |
|
Glioblastoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
We report the frequency of IDH mutations in a large cohort of nearly 1550 patients, EGFR amplifications in almost 1900 IDH-wildtype glioblastomas, and histone mutations in 70 adult gliomas.
|
30786920 |
2019 |
|
Glioblastoma
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Clinically, we used <sup>68</sup>Ga-labeled FAPI-02/04 for PET imaging in 18 glioma patients (five IDH-mutant gliomas, 13 IDH-wildtype glioblastomas).
|
31388723 |
2019 |
|
Glioblastoma
|
0.200 |
Biomarker
|
disease |
BEFREE |
PD-L1 expression was significantly higher in H3K27M/IDH1 double-negative adult glioblastomas (GBMs) (P = 0.002).
|
31625205 |
2019 |
|
Glioblastoma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Our results support high ALDOC expression in glioblastomas that might imply the mutated status of IDH1, less possibility of mesenchymal subtype, and predict a favorable prognosis.
|
31450822 |
2019 |